The Tumor and Host Response (TIHR) program is a newly developed, interdisciplinary research group that focuses on the interaction between immunity and cancer. Investigators of the TIHR program perform basic and translational research aimed at understanding the role of Immune/Inflammatory responses in the pathogenesis of cancer and the application of these discoveries to the treatment of cancer. The program is comprised of 20 members from six different departments with a total annual direct research support of $6,542,810 of which $1,786,734 is from the NCI. Over this last grant period, there were 352 publications of the Tumor Immunology and Host Response Program, of which 13,6% are intra-programmatic and 34.7% are inter-programmatic. Investigators are involved in many intra- and inter-programatic interactions and collaborate with researchers in other University of Michigan Comprehensive Cancer Center programs including Cancer Cell Biology, Breast Oncology, Prostate Oncology, and Head and Neck Oncology. The program has recently joined the Translational Research Cancer Consortium (TRC3), consisting of Immunology programs of major Comprehensive Cancer Centers in the region, The TIHR program has three main research themes: (1) to elucidate the mechanisms that regulate the interaction between cancer cells and the Innate and adaptive immune systems;(2) development of novel approaches to enhance immune responses against cancer cells;and (3) the translation of novel discoveries from the laboratory to the clinic for cancer treatment.
The program studies how the immune system interacts with tumor cells during cancer development. Our work will not only provide opportunity to induce better immune response for cancer prevention and therapy, but also elucidate critical host factors that facilitate cancer development for targeted cancer therapy.
|Lee, Alice W; Ness, Roberta B; Roman, Lynda D et al. (2016) Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet Gynecol 127:828-36|
|Mathewson, Nathan D; Jenq, Robert; Mathew, Anna V et al. (2016) Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 17:505-13|
|Owen, John Henry; Graham, Martin P; Chinn, Steven B et al. (2016) Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head Neck 38 Suppl 1:E459-67|
|Peng, Dongjun; Tanikawa, Takashi; Li, Wei et al. (2016) Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 76:3156-65|
|Kadakia, Kunal C; Snyder, Claire F; Kidwell, Kelley M et al. (2016) Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21:539-46|
|Boonstra, Philip S; Mukherjee, Bhramar; Gruber, Stephen B et al. (2016) Tests for Gene-Environment Interactions and Joint Effects With Exposure Misclassification. Am J Epidemiol 183:237-47|
|Amin, Nisar A; Malek, Sami N (2016) Gene mutations in chronic lymphocytic leukemia. Semin Oncol 43:215-21|
|Hardiman, Karin M; Ulintz, Peter J; Kuick, Rork D et al. (2016) Intra-tumor genetic heterogeneity in rectal cancer. Lab Invest 96:4-15|
|Boonstra, Philip S; Taylor, Jeremy M G; Smolska-Ciszewska, Beata et al. (2016) Alpha/beta (Î±/Î²) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol 89:20150957|
|Di Girolamo, Daniela; Ambrosio, Raffaele; De Stefano, Maria A et al. (2016) Reciprocal interplay between thyroid hormone and microRNA-21 regulates hedgehog pathway-driven skin tumorigenesis. J Clin Invest 126:2308-20|
Showing the most recent 10 out of 1165 publications